---
title: "Theriva Biologics, Inc. (TOVX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TOVX.US.md"
symbol: "TOVX.US"
name: "Theriva Biologics, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T18:32:21.472Z"
locales:
  - [en](https://longbridge.com/en/quote/TOVX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TOVX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TOVX.US.md)
---

# Theriva Biologics, Inc. (TOVX.US)

## Company Overview

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [erivabio.com](https://erivabio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:18.000Z

**Overall: D (0.70)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 306 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 7.43% |  |
| P/B Ratio | 0.89 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 13767800.40 |  |
| Revenue | 300000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -148.69% | E |
| Profit Margin | -7153.00% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | 7.43% | C |
| Total Assets YoY | 18.93% | A |
| Net Assets YoY | -0.63% | D |
| Cash Flow Margin | 62.56% | C |
| OCF YoY | 0.00% | D |
| Turnover | 0.01 | E |
| Gearing Ratio | 59.74% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Theriva Biologics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "7.43%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.89",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "13767800.40",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "300000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-148.69%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-7153.00%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "7.43%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "18.93%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.63%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "62.56%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "59.74%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.60 | 147/385 | - | - | - |
| PB | 0.89 | 78/385 | 1.06 | 0.63 | 0.27 |
| PS (TTM) | 45.89 | 229/385 | 54.15 | 49.24 | 45.14 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-06T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 50% |
| Overweight | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.29 |
| Highest Target | 4.00 |
| Lowest Target | 1.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TOVX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TOVX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TOVX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TOVX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**